10-Q quarterly report · filed Nov 4, 2026

Tenaya Therapeutics Inc (TNYA) Q3 2026 10-Q Quarterly Report

Short answer

Tenaya Therapeutics Inc (TNYA) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2M with net income of −$19M.

Q3 2026 key financials · XBRL

Revenue
$2M
+52.9% QoQ
Net income
−$19M
+6.6% YoY · +56.4% QoQ
Operating margin
-1153.3%
EPS (diluted)
−$0.08
+27.3% YoY · +60.0% QoQ

Source: XBRL data from the Tenaya Therapeutics Inc (TNYA) Q3 2026 10-Q on SEC EDGAR. USD.

Tenaya Therapeutics Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $1.7M, versus none YoY, entirely collaboration revenue
  • Net loss $18.9M vs $20.3M YoY, operating loss $19.6M vs $20.9M
  • Clinical R&D highest-performing category, $6.2M, up 52% YoY; manufacturing lowest, $1.5M, down 64%
  • Cash and equivalents $66.8M at September 30, 2026; operating cash use $40.5M year-to-date
  • Outlook: cash sufficient through at least next twelve months; pivotal-trial regulatory updates planned by year end

Risk Factors

  • Newly added tax risk: California’s temporary state NOL suspension applies to taxable years 2024, 2025 and 2026
  • Manufacturing risk: Closure of the GMMC may require comparability studies, regulatory filings and facility approvals for TN-201 and TN-401
  • Regulatory risk: February 2026 legislation permits FDA approval of multiple versions of orphan drugs across subindications and subpopulations
  • Operational risk: FDA placed MyPEAK-1 on clinical hold in November 2025, later lifted after protocol amendments
  • Financial risk: Cash and cash equivalents totaled $66.8 million at September 30, 2026, against an accumulated deficit of $686.6 million

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.